CTSO
Cytosorbents Crp
3.80$
+1.6%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 41.3% | 31.9% | 23.5% | 26.5% | 47.7% | -2.7% | 28.9% | 29.1% | 29.7% | 26.3% | 30.8% | 26.8% | 28.4% | |
| 58.7% | 68.1% | 76.5% | 73.5% | 52.3% | 102.7% | 71.1% | 70.9% | 70.3% | 73.7% | 69.2% | 73.2% | 71.6% | |
| 48.4% | 55.7% | 25.0% | 17.2% | 21.5% | 14.2% | 19.1% | 13.1% | 9.7% | 13.5% | 11.6% | 15.1% | 12.5% | |
| 118.7% | 143.7% | 102.9% | 95.0% | 90.9% | 22.0% | 96.6% | 95.3% | 90.8% | 102.2% | 91.9% | 82.7% | 91.8% | |
| 153.5% | 199.3% | 128.3% | 113.9% | 103.3% | 146.9% | 115.7% | 108.4% | 100.5% | 115.6% | 103.5% | 100.6% | 105.0% | |
| -94.8% | -131.2% | -51.8% | -40.4% | -51.0% | -44.2% | -44.5% | -37.6% | -30.2% | -42.0% | -34.3% | -27.4% | -33.4% | |
| 0.4% | 0.7% | 0.1% | 2.0% | 6.8% | 6.8% | 6.9% | 6.4% | 6.8% | 8.1% | 9.7% | 9.0% | 8.4% | |
| -118.6% | -94.6% | -67.7% | -48.6% | -27.1% | -104.6% | -16.9% | 20.2% | -37.6% | -59.5% | -57.9% | -45.9% | -50.0% | |
| -5.5% | -11.1% | 0.0% | 0.0% | – | -18.5% | – | – | -4.2% | – | – | – | – | |
| -118.6% | -83.5% | -67.7% | -48.6% | -27.1% | -86.2% | -16.9% | 20.2% | -33.4% | -59.5% | -57.9% | -45.9% | -48.9% | |
| -112.2% | -83.1% | -62.7% | -41.5% | -15.3% | -93.2% | -5.4% | 31.2% | -26.6% | -47.3% | -44.0% | -32.9% | -37.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.